Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ANDN revoked:
http://www.sec.gov/litigation/admin/2016/34-76898.pdf
Perfect play with investors money. The CEO has to quit
Yeah. See the 10K how much shares have been sold at peanuts. Are you telling me CEO doesn't know? Hahaha
The guy did not sell one share. Get your facts straight!
So I am right the CEO is useless and has to go. How can he sell shares for peanuts and expect the PPS to go up? No money in the company.
It was proven. Read the publications. The share price doesn't reflect the company at all!
Tech is yet to be proven. It is a never ending development. Focus of share holders like myself is the performance of ANDN which is horrible.
You sell shares for peanuts and expect us to pay for your mistakes? Change of CEO is what is needed.
This company has good technology. Follow their developments
This company has good technology. Follow what the are developing.
This company is done. They sold their shares for 0.008 as per their filing and sold further shares for 0.001. No future for this company.
Pathetic company. Zero volume. I thought being a Jewish company it will do better. It seems novices are running the company and it has no more cash!
Peptide Booster for Anti-wrinkle Cosmeceuticals
Our subsidiary, NBCT Ltd., has developed an intra-dermal nano-technology enhancing skin penetration of collagen generating peptides in cosmetic anti-wrinkle products, and is preparing for clinical trials to be conducted in 2012.
NBCT lipid-based nano-particles deliver peptides to the dermis, and provide:
§ efficient transport of peptides through the epidermis without physical or chemical changes in the skin barrier properties for other materials.
§ effective protection of peptides from degradation by skin enzymes.
§ controlled release of the peptides at the dermis.
§ the penetration mechanism does not alter the skin properties.
§ particles pass through the epidermis to the dermis, form an active-agent payload deposit in the dermis that act to prevent any amino acids attacking the payload.
§ particles have a controlled release mechanism for the active agent payload deposit directly to the dermis.
Directed Stem Cells toward Myogenic Cells
http://www.andaininc.com/Default.asp?sType=0&PageId=19
Our subsidiary OrCell Ltd. has developed an innovative stem cell technology for healing and rehabilitating of severally damaged muscle tissue and initiating strong Myogenetic regeneration in injuries such as Myocardial Infarction (MI), pressure ulcers, and regenerative diseases of muscle.
Our innovative technology is based on precise control of stem cell transformation directed solely toward myogenic cells . This unique process allows myogenic cells working as a network (similar to the cells of skeletal and heart muscle tissue) suitable for transplantation use.
For human treatment, OrCell Myogenic cells derived from MSC's that are isolated from adipose (fat) or bone marrow tissue. Our unique procedure prevents the formation of spontaneously differentiated stem cells that may potentially form tissues such as bone tissue, cartilage, etc. along with blocking tumorgenecity which may develop in muscular tissue undergoing healing after transplantation.
Apart from our unique technology, there is no existing protocol that allows safe and efficient direction of stem cells into myogenic cells for human transplantation and human tissue engineering. Our protocol enables safe human therapy without side effects and is integrated into the injured tissue without body rejection or suppressive immunological medical treatment.
The Company has completed successful animal studies with extremely positive results.
L2 thin for ANDN and all good things to research as this co. is up and coming...
Ultrasonic Catheter
The SonoGuide is our technology breakthrough device for recurrent fatal brain cancer.
The SonoGuide, which was developed by our subsidiary Sonenco Ltd., is practically the only viable solution that can deliver chemotherapy to brain tumors.
The SonoGuide leading tip ultrasonic vibrations disperse heavy nano-particles carrying chemotherapy agents. The ultrasonic vibration “shoots” the nano-particles into the malignant tissue area.
The Sonoguide is administered to the brain tumor via a standard stereotactic procedure, which only takes a few minutes.
Sonenco has completed animal studies that show an outstanding dispersion performance, with no damage to the healthy brain tissue and the animal subject.
Competitive Advantage
SonoGuide’s superior solution offers the following advantages:
Minimal invasive short procedure (a few minutes).
Ability to administer large volumes of drug dispersion.
Continuous target site drug exposure..
Energy for maximum efficient dispersion is well below medical energy level restrictions.
Precise dispersion profile to meet medical demands derived from fine-tuning and adjustment flexibility by effective use of all eadjustable parameters.
andn
ANDN > Miniature Insulin Pump
We have developed a novel ultra slim, small, patch size, all disposable Insulin Pump, suitable for type-I and type-II diabetics.
The Insulin pump is of miniature size. It holds 5 CC insulin, weighs 25 grams, and is 49mm in diameter by 7 mm thick.
The disposable low cost pump may offer an affordable yet clinically superior replacement to the insulin pen injector.
The pump provides safe and constant Insulin treatment to diabetics for a week of use. It is much more accurate than existing pumps in the market.
Our pump is attached to the patient’s body as a Band-Aid patch. Its small size and ultra low profile makes it virtually unnoticeable and very comfortable to wear. Our patients feel comfortable to bathe, sport, and swim with it attached.
The direct attachment to the body requires no tubing like in a conventional insulin pump, and it provides a real-time alert for occlusions and leakages.
Our pump is fully programmed by a remote control unit capable to dynamically change the Insulin treatment program, and actively monitor insulin dosage to the patient. The control unit updates information to the patient, the doctor or the health provider.
It can also function without the control unit by using pre-programmed treatments, providing safe Basal Insulin treatment and allows delivery of manual Bolus dosages. A fail-safe mechanism prevents administration of multiple Boluses to prevent hypo-glycaemia.
$$ANDN is looking good, green and up 25%!
ANDN > Andain commercializes novel technologies in the biotech & medical fields.
Our Professional team seeks to enhance our core product lines with synergetic advanced technologies and products.
Together with our industrial partners we operate an incubator program to ensure timely market presence of each product we develop.
$$ANDN: I agree, this is off to a good start.
ANDN is up +140.00% since the 52Wk Low of 0.0250 on 3/20/13
ANDN 20-Day Moving Averages
Moving Average - 0.0457 Price Change - +0.0250 Percent Change - +71.43% Average Volume
- 21,050
Here's the Company Website:
http://www.andaininc.com/
ANDN
ANDN, nice volume, it's green ,and chart looking great !
last news > April 29, 2013 /PRNewswire via COMTEX/ -- Andain Inc. (OTCBB: ANDN) ("Andain" or the "Company"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its accelerating incubator program, announces today its innovative nano-particles drug delivery technology.
Andain completed the development of innovative lipid-based drug delivery nano-particles capable of carrying hydrophilic and hydrophobic drugs to a targeted human organ with timely drug release capabilities. After the nano-particles release the drug directly to the targeted organ, they brake-down to their natural ingredients and are absorbed into the natural metabolism with no adverse affects.
Established in 2004 as a Nevada corporation with locations in Israel and the US, Andain commercializes novel technologies in the biotechnology and medical fields, specializing in identifying technical innovations and providing a unique incubator/accelerator development and industrial platform. The Company also offers technical know-how and business strategy expertise to commercialize new technologies and deliver shareholder value
ANDN intends to approach the initial market segment of respiratory intensive care units to treat VAP (ventilator-associated pneumonia), which is commonly associated with multi-drug-resistant (MDR) virulent bacteria causing over than 50% mortality rate.
ANDN has successfully developed an inhaled solution for the treatment of COPD (Chronic Obstructive Pulmonary Disease), which affects over 16 million patients in the USA alone, and is the No. 4 clinical cause of death after heart failure, cancer and stroke.
$$ANDN: The Company's intra-dermal delivery technology results in a safe way to deliver generic collagen generating boosters to the skin. The nano-particles shield the peptide from enzyme reaction all the way from the skin surface, through all the skin layers to the dermis. These shilling properties provide outstanding delivery properties, reducing the needed peptide quantity to 1/8 - 1/10 from normal peptide dosage use. Treatment increases by the adhesives properties to the collagen generating skin cells and timely peptides release a mechanism for prolonged treatment.
ANDN green and looking great so far, glad I jumped on this !
$$ANDN~Competitive Advantage for Ultrasonic Catheter:
SonoGuide’s superior solution offers the following advantages:
Minimal invasive short procedure (a few minutes).
Ability to administer large volumes of drug dispersion.
Continuous target site drug exposure..
Energy for maximum efficient dispersion is well below medical energy level restrictions.
Precise dispersion profile to meet medical demands derived from fine-tuning and adjustment flexibility by effective use of all eadjustable parameters.
it will come. ANDN looking very attractive this am, imo.
good move since April> andn was 0.025 !!!
$$ANDN~Ultrasonic Catheter:
The SonoGuide is our technology breakthrough device for recurrent fatal brain cancer.
The SonoGuide, which was developed by our subsidiary Sonenco Ltd., is practically the only viable solution that can deliver chemotherapy to brain tumors.
The SonoGuide leading tip ultrasonic vibrations disperse heavy nano-particles carrying chemotherapy agents. The ultrasonic vibration “shoots” the nano-particles into the malignant tissue area.
The Sonoguide is administered to the brain tumor via a standard stereotactic procedure, which only takes a few minutes.
Sonenco has completed animal studies that show an outstanding dispersion performance, with no damage to the healthy brain tissue and the animal subject.
waiting to see some GOOD volume hitting ...
she looking thin'
ANDN is, and usually that's a sign this will make a solid push up !
ANDN Headlines:
Apr 29, 2013 Andain Inc. Announces its Innovative Organ-targeted Drug Delivery Nano-particles
Apr 10, 2013 Andain Inc. Announces Successful 510K Tests of its Breakthrough Miniature Disposable Insulin Pump
Apr 2, 2013 Andain Inc. Discusses and Provides Update on its Breakthrough Stem Cell Therapy for the Treatment and Regeneration of Severely Damaged Muscle Tissue
Market Value1 $3,460,155 a/o Jun 03, 2013
ANDN is churning here
Saw that, thanks Den...ANDN will have a big day today, imo !
LOW Shares Outstanding 57,669,242 a/o Mar 31, 2013
LOW Shares Outstanding 57,669,242 a/o Mar 31, 2013
low Authorized Shares 500,000,000 a/o Dec 31, 2010
ANDN Share Structure
Market Value $3,460,155 a/o Jun 03, 2013
Shares Outstanding 57,669,242 a/o Mar 31, 2013
Float Not Available
Authorized Shares 500,000,000 a/o Dec 31, 2010
Par Value 0.001
ANDN getting some nice play this am !
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
85
|
Created
|
09/29/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |